Tandem Diabetes Care financials
$16.57+0.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.6M | $247.2M | $290.4M | $249.3M | $240.7M | $234.4M | $282.6M | $244.0M | $221.9M | $191.7M | $196.8M | $185.6M |
| Gross profit | $144.8M | $136.8M | $167.5M | $134.3M | $125.9M | $118.4M | $157.5M | $124.7M | $112.8M | $94.7M | $93.3M | $89.8M |
| Gross margin | 56.9% | 55.3% | 57.7% | 53.9% | 52.3% | 50.5% | 55.7% | 51.1% | 50.8% | 49.4% | 47.4% | 48.4% |
| Operating income | -$13.8M | -$17.4M | $8.3M | -$22.9M | -$51.8M | -$120.9M | -$582.0K | -$26.1M | -$30.8M | -$41.7M | -$35.1M | -$31.5M |
| Net income | -$21.2M | -$20.4M | -$589.0K | -$21.2M | -$52.4M | -$130.6M | $755.0K | -$23.3M | -$30.8M | -$42.7M | -$30.0M | -$33.0M |
| Net margin | −8.3% | −8.2% | −0.2% | −8.5% | −21.8% | −55.7% | 0.3% | −9.5% | −13.9% | −22.3% | −15.2% | −17.8% |
| Diluted EPS | $-0.31 | $-0.30 | $-0.01 | $-0.31 | $-0.78 | $-1.97 | $0.01 | $-0.35 | $-0.47 | $-0.65 | $-0.46 | $-0.51 |
| EBITDA | -$9.3M | -$12.9M | $12.8M | -$18.4M | -$27.5M | -$41.4M | $3.7M | -$21.9M | -$26.7M | -$37.6M | -$35.1M | -$27.5M |
| Operating cash flow | -$34.6M | $11.1M | $9.8M | $8.3M | -$9.5M | -$18.3M | $10.7M | $26.8M | -$5.3M | -$8.0M | -$7.2M | $55.0K |
| Free cash flow | -$38.7M | $4.8M | -$75.5M | $4.2M | -$15.7M | -$21.2M | $7.6M | $21.5M | -$11.7M | -$12.5M | -$81.9M | -$5.3M |
| Diluted shares | 69.0M | 68.4M | 68.0M | 67.7M | 67.1M | 66.4M | 65.9M | 65.5M | 65.0M | 65.3M | 65.4M | 65.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $62.8M | $179.3M | $90.6M | $91.9M | $64.1M | $53.6M |
| Short-term investments | $393.2M | $390.9M | $202.0M | $227.2M | $251.2M | $315.1M |
| Total debt | $602.6M | $601.8M | $310.0M | $309.6M | $309.1M | $349.4M |
| Total assets | $1.15B | $1.15B | $881.1M | $874.7M | $875.7M | $922.1M |
| Total liabilities | $1.02B | $1.02B | $725.9M | $741.7M | $742.5M | $766.9M |
| Shareholders' equity | $130.4M | $132.4M | $155.2M | $133.0M | $133.3M | $155.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology